CJC-1295 DAC (2mg Vial) Dosage Protocol

Quickstart Highlights

CJC-1295 DAC (2mg) dosage protocol is designed to elevate and prolong growth hormone (GH) and IGF-1 levels via once-weekly subcutaneous injections.

  • Extended half-life allows weekly administration
  • Typical dosing ranges from 0.3 mg to 2 mg per week in standard protocols
  • Advanced protocols may go beyond 2 mg weekly
  • Reconstitute to a practical concentration for accurate dosing
  • Store lyophilized vials frozen; refrigerate after reconstitution
CJC-1295 DAC Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and once-weekly dosing protocol

Standard / Gradual Approach (0.8 mL = 2.5 mg/mL)

Week Weekly Dose (mg) Units (per injection)
Weeks 1–4 0.3 mg 12 units
Weeks 5–8 0.6 mg 24 units
Weeks 9–12 1 mg 40 units
Weeks 13–16 (Optional) 2 mg 80 units

Ideal for moderate weekly doses (up to ~2 mg). Reconstitute each 2 mg vial with 0.8 mL of bacteriostatic water to create a 2.5 mg/mL solution.

  1. Draw 0.8 mL of bacteriostatic water into a sterile syringe.
  2. Inject the water slowly along the vial wall to minimize foaming.
  3. Gently swirl—avoid vigorous shaking.
  4. Label the vial with the date and store at 2–8°C (refrigerator).
  5. Use within 30 days; avoid repeated freeze-thaw cycles.

Note: For higher doses (e.g., 2 mg in Weeks 13–16), you will use the entire vial in a single injection (80 units). Multiple vials may be required to sustain the full protocol.

Advanced / Aggressive Approach (0.4 mL = 5 mg/mL)

Week Weekly Dose (mg) Units (per injection)
Weeks 1–4 1 mg 20 units
Weeks 5–8 2 mg 40 units
Weeks 9–12 3 mg 60 units
Weeks 13–16 (Optional) 4 mg 80 units

Recommended if aiming for higher weekly doses (1–4 mg). Reconstitute each 2 mg vial with 0.4 mL of bacteriostatic water to create a 5 mg/mL solution.
Important: If your protocol calls for 3 mg or 4 mg in a single week, you will need multiple vials, as one vial only contains 2 mg total.

  1. Draw 0.4 mL of bacteriostatic water into a sterile syringe.
  2. Slowly inject the water along the vial wall to reduce foaming.
  3. Gently roll or swirl the vial—avoid vigorous shaking.
  4. Refrigerate at 2–8°C and use within 30 days.
  5. Avoid multiple freeze-thaw cycles.

Note: This guide is for educational purposes only. Always consult with a qualified healthcare professional.

Protocol Overview

A concise summary of this once-weekly regimen.

  • Goal: Sustain elevated GH and IGF-1 levels for research purposes
  • Schedule: Weekly subcutaneous injections for 8–16 weeks
  • Dose Range: 0.3 mg to 2 mg weekly (standard), up to 4 mg (advanced)
  • Reconstitution: Use smaller volumes (0.4–0.8 mL) to match targeted units
  • Storage: Keep lyophilized vials frozen; refrigerate after reconstitution

Dosing Protocol

Suggested once-weekly injection approach for stable and prolonged action.

  • Weekly Dose: Start at 0.3 mg; gradually increase as research requires
  • Frequency: Inject once per week subcutaneously
  • Cycle Length: 8–16 weeks (can be extended based on objectives)
  • Maximum Dose: Some protocols reach up to 4 mg weekly (requires multiple vials)
  • Timing: Generally consistent day/time each week

Storage Instructions

Proper storage ensures peptide integrity.

  • Lyophilized: Freeze until mixing (−20°C) or keep refrigerated if used soon
  • Reconstituted: Refrigerate at 2–8°C
  • Use within 30 days of mixing
  • Avoid repeated freeze-thaw cycles

Supplies Needed

Ensure you have these on hand for an 8–16 week cycle (multiple vials required if dosing above 0.3–0.6 mg for extended weeks).

  • Peptide Vials (2 mg each):
    • 8 wks ≈ 2 vials (if standard protocol starts at 0.3 mg, then 0.6 mg)
    • 12 wks ≈ 4 vials (increasing up to 1 mg weekly)
    • 16 wks ≈ 8+ vials (if final weeks reach 2 mg or more)
  • Insulin Syringes:
    • 8 wks ≈ 8
    • 12 wks ≈ 12
    • 16 wks ≈ 16
    (Use smaller syringes if under 10 units per injection is unavoidable)
  • Bacteriostatic Water: 1× 30ml
  • Alcohol Swabs: 1 box
CJC-1295 DAC Vial View Supplier
Insulin Syringes View Supplier
Bacteriostatic Water View Supplier
Alcohol Pads View Supplier

Important Notes

Practical tips to enhance safety and consistency.

  • Always use new, sterile insulin syringes and rotate injection sites.
  • Administer weekly injections at the same time each week for consistent results.
  • Monitor for any adverse reactions; discontinue if concerns arise.
  • Log your weekly dosing and track progression over the research period.

How This Works

CJC-1295 DAC is a modified growth hormone-releasing hormone (GHRH) analog with a significantly extended half-life.

  • DAC Modification: Extends half-life to maintain elevated GH and IGF-1
  • GH Release: Stimulates the pituitary for sustained GH pulses
  • Research Potential: Explored for muscle support, recovery, and metabolic studies

Potential Benefits & Side Effects

Individual responses can vary based on dosage and research objectives.

  • May support improvements in muscle recovery and lean mass (research basis)
  • Possible supportive role in fat metabolism
  • Side effects may include mild injection-site redness or transient flushing
  • Rarely, users report headache, water retention, or joint discomfort

Lifestyle Factors

Complementary methods for maximizing potential outcomes.

  • Adopt a balanced, protein-rich diet for research on body composition
  • Include regular exercise protocols with adequate rest
  • Manage stress and maintain consistent sleep patterns

Injection Technique

Simple guidelines for safe daily injections.

  • Clean vial rubber stopper & injection site with alcohol swabs
  • Insert needle at a 45–90° angle into subcutaneous tissue
  • Inject slowly & rotate sites (abdomen, thigh, etc.)

Important Note

This guide is for educational purposes only. Always consult a qualified healthcare provider before starting or modifying any therapy.

References

  • FDA Document – Regulatory attachment for CJC-1295
    View Source
  • PubMed – Clinical study on CJC-1295
    View Source
  • FDA Document – Additional regulatory data on CJC-1295
    View Source
  • American Journal of Physiology – GH regulation research article
    View Source
  • Tocris – Peptide reconstitution calculator
    View Source
  • Journal of Clinical Endocrinology & Metabolism – CJC-1295 GH modulation study
    View Source
  • PubMed – Additional CJC-1295 research data
    View Source

 

Enhanced Footer Example